TLR4 is an inflammatory receptor belonging to the class of Pattern Recognition Receptor (PRRs), whose function is to sense Pathogens or Damages Associated Molecular Patterns (PAMPs, DAMPs) and start the innate immune response.1 The natural ligand of TLR4 is Lipopolysaccharide (LPS), an essential component of Gram-negative bacteria outer membrane.1,2 The minimal portion of LPS required for immunogenicity is a glycolipid called Lipid A.2 Through molecular simplification starting from Lipid A, our group developed two new compounds which showed promising TLR4 antagonism: FP7 (Fig. 1, a) and FP12 (Fig.1, b) (HEK-Blue hTLR4 IC50 = 2.0 and 0.63 µM; RAW-Blue TLR4 IC50 = 7.7 and 1.7 µM).3,4 Figure 1: TLR4 antagonists developed by our group. The aim of this work is to produce novel TLR4 antagonists. This goal will be achieved modifying the substituent on the anomeric position of FP7 and FP12 to increase stability for further functionalization of the C6 position. Furthermore, starting form promising natural compounds active as TLR4 antagonists, computer assisted docking will be applied to select new scaffolds to be synthetized and chemically modified.

Lami, F., Romerio, A., Italia, A., Shaik, M., Martin-Santamaria, S., Peri, F. (2024). Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists. Intervento presentato a: SCI 2024, Elements for the future - 26-30 agosto, Milano, Italia.

Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists

Lami, F
Primo
;
Romerio, A;Italia, A;Shaik, M M;Peri, F
2024

Abstract

TLR4 is an inflammatory receptor belonging to the class of Pattern Recognition Receptor (PRRs), whose function is to sense Pathogens or Damages Associated Molecular Patterns (PAMPs, DAMPs) and start the innate immune response.1 The natural ligand of TLR4 is Lipopolysaccharide (LPS), an essential component of Gram-negative bacteria outer membrane.1,2 The minimal portion of LPS required for immunogenicity is a glycolipid called Lipid A.2 Through molecular simplification starting from Lipid A, our group developed two new compounds which showed promising TLR4 antagonism: FP7 (Fig. 1, a) and FP12 (Fig.1, b) (HEK-Blue hTLR4 IC50 = 2.0 and 0.63 µM; RAW-Blue TLR4 IC50 = 7.7 and 1.7 µM).3,4 Figure 1: TLR4 antagonists developed by our group. The aim of this work is to produce novel TLR4 antagonists. This goal will be achieved modifying the substituent on the anomeric position of FP7 and FP12 to increase stability for further functionalization of the C6 position. Furthermore, starting form promising natural compounds active as TLR4 antagonists, computer assisted docking will be applied to select new scaffolds to be synthetized and chemically modified.
poster
TLR4, inflammation, natural compounds
English
SCI 2024, Elements for the future - 26-30 agosto
2024
2024
open
Lami, F., Romerio, A., Italia, A., Shaik, M., Martin-Santamaria, S., Peri, F. (2024). Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists. Intervento presentato a: SCI 2024, Elements for the future - 26-30 agosto, Milano, Italia.
File in questo prodotto:
File Dimensione Formato  
Lami-2024-SCI2024-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Dominio pubblico
Dimensione 456.18 kB
Formato Adobe PDF
456.18 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/508380
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact